Cationic lipids for intracellular delivery of biologically active molecules

• US 5,459,127 A
• Filed: 09/16/1993
• Issued: 10/17/1995
• Est. Priority Date: 04/19/1990
• Status: Expired due to Term

• Current Assignee: Vical, Inc. (Fresh Tracks Therapeutics, Inc.)
• Original Assignee: Vical, Inc. (Fresh Tracks Therapeutics, Inc.)
• Inventors: Hwang-Felgner, Jiin-Yu, Border, Richard C., Kumar, Raj, Felgner, Philip L., Basava, Channa
• Primary Examiner(s): Killos, Paul J.
• Application Number:
  US08/123,757
• Time in Patent Office: 761 Days
• Field of Search: 514/2, 514/7
• US Class Current: 424/450
• CPC Class Codes: A61K 47/186 Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
• CPC Class Codes: A61K 47/54 the modifying agent being an organic compound
• CPC Class Codes: A61K 47/544 Phospholipids
• CPC Class Codes: A61K 47/645 Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
• CPC Class Codes: A61K 9/0014 Skin, i.e. galenical aspects of topical compositions non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00
• CPC Class Codes: A61K 9/0019 Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner non-active ingredients are additionally classified in A61K47/00
• CPC Class Codes: A61K 9/1272 with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids with cholesterol as the only non-phosphatidyl surfactant A61K9/127; lipids as modifying agent A61K47/543
• CPC Class Codes: A61P 31/12 Antivirals
• CPC Class Codes: C12N 15/88 using microencapsulation, e.g. using amphiphile liposome vesicle

Abstract

Disclosed are cationic lipids capable of facilitating transport of biologically active agents into cells, including the transfection of cells by therapeutic polynucleotides, the delivery of antiviral drugs, and the introduction of immunogenic peptides. The cationic lipids, comprising an ammonium group, have the general structure ##STR1## Also disclosed are adducts of these compounds comprising additional cationic sites that enhance the transfective or transport activity. Structure-activity correlations provide for the selection of preferred compounds to be synthesized for this purpose. Compositions disclosed for use of these cationic lipid include formulations for in vitro transfection and pharmaceutical formulations for parenteral and topical administration of therapeutic agents.

Claims

1. A formulation for transfection of polynucleotides into cells, comprising a cationic lipid and an effective transfection-promoting amount of a lysophosphatide, having the structure ##STR20## wherein Y is selected from the group consisting of --O--CH2-- and --O--C(O)--;

R is C₁₀ to C₂₃ alkyl or alkenyl; and

Z is a phospholipid headgroup.

2. A formulation for transfection of polynucleotides and peptides into cells, comprising a compound having the structure ##STR21## wherein Y¹ and Y² are the same or different and are --O--C(O)-- or --O--;

R¹ is H, or C₁ to C₂₄ alkyl or alkenyl;

R² is C₁ to C₂₄ alkyl or alkenyl;

R³ and R⁴ are independently C₁ to C₂₄ alkyl or H;

R⁵ is C₁ to C₂₄ alkyl straight chain or branched chain;

R⁶ is --C(O)--(CH₂)_m --NH--, a diaminocarboxylate ester group which is alkyl, aryl, or aralkyl, or --C(O)--(CH₂)_m --NH-- linked to said diaminocarboxylate ester group, or is absent;

R⁷ is H, spermine, spermidine, a histone, or a protein with DNA-binding specificity, or the same groups wherein the amine functionalities of the R⁷ moiety are quaternized with R³, R⁴, or R⁵ groups;

or

R⁷ is an L- or D-alpha amino acid having a positively charged group on the side chain, said amino acids comprising arginine, histidine, lysine or ornithine or analogues thereof, or wherein the amine of the R⁷ moiety is quaternized with R³, R⁴ or R⁵ groups;

or

R⁷ is a polypeptide selected from the group consisting of L- or D-alpha amino acids, wherein at least one of the amino acids residues comprises arginine, histidine, lysine, ornithine, or analogues thereof;

n is 1 to 8;

m is 1 to 18; and

X is non-toxic anion.

5. A formulation according to claims 2 or 3, wherein said lysophosphatide is selected from the group consisting of lysophosphatidylcholine and lysophosphatidylethanolamine.

6. A formulation according to claim 5, wherein said lysophosphatide is a mono-oleoyl lysophosphatidylcholine.

7. A formulation according to claim 2 or 3, wherein said lysophosphatide has a negatively charged headgroup.

8. A formulation according to claim 2 or 3, wherein said lysophosphatide has a neutrally charged headgroup.

9. A formulation according to claim 2 or 3, wherein the molar ratio of said lysophosphatide to cationic lipid is less than about 0.50.

10. A formulation comprising a cationic lipid and a lysophosphatide, wherein said cationic lipid is selected from the group consisting of DOTMA, DOTAP, and compounds having a structure set forth in claim 2 or 3.

11. A lipid formulation for the transfection of polynucleotides and peptides into cells, comprising a cationic lipid or combination of cationic lipids selected from the group consisting of DOTMA, DOTAP, or a structure according to claim 2 or 3, wherein an effective transfection-promoting amount of said cationic lipids up to about one-third of the total cationic lipids are selected from species wherein Y¹ and R¹ or Y² and R² of said structure, or moieties of DOTMA or DOTAP corresponding thereto, are hydroxyl groups.

12. A liposomal formulation, comprising a cationic lipid according to claim 2 or 3, or a mixture of said cationic lipids, said lipid or mixture of lipids being in the form of vesicles in an aqueous media.

13. A liposomal formulation according to claim 12, further comprising a neutral lipid species, selected from the group consisting of phosphatidylethanolamine, phosphatidylcholine, sphingomyelin, or cholesterol.

14. A liposomal formulation according to claim 13 wherein the molar ratio of said cationic lipid species to said neutral lipid species is from about 9/1 to 1/9.

15. A liposomal formulation according to claim 13 wherein said molar ratio is about 5/5.

16. A liposomal formulation according to claim 13 further comprising a lyso lipid selected from the group consisting of lysophosphatidylcholine, lysophosphatidylethanolamine, or a lyso form of a cationic lipid species.

17. A pharmaceutical product comprising a cationic lipid having a structure set forth in claim 2 or 3, together with a pharmacologically effective amount of therapeutic agent.

18. A pharmaceutical product according to claim 17, wherein said therapeutic agent is a corticosteroid or a non-steroidal anti-inflammatory agent.

19. A pharmaceutical product according to claim 17, wherein said therapeutic agent is a therapeutically effective nucleoside analogue or nucleotide analogue.

20. A pharmaceutical product according to claim 18, wherein said therapeutic agent is a phosphatidyl derivative or diphosphate diglyceride derivative of said analogue.

21. A pharmaceutical product according to claim 17, wherein said analogue is dideoxynucleoside, a didehydronucleoside, a halogenated or azido derivative of a nucleoside, or an acyclic nucleoside.

22. A pharmaceutical product according to claim 19, wherein said analogue is an antiviral nucleoside selected from the group consisting of a 3'"'"'-azido-2'"'"',3'"'"'-dideoxypyrimidine, a 3'"'"'-halopyrimidine dideoxynucleoside, or a 2'"'"',3'"'"'-didehydro-2'"'"',3'"'"'-dideoxynucleoside.

23. A pharmaceutical product according to claim 22, wherein said analogue is an antiviral nucleoside which is 3'"'"'-azido-3'"'"'-deoxythymidine (AZT).

24. A pharmaceutical product according to claim 21, wherein said analogue is an antiviral nucleoside selected from the group consisting of acyclovir, gancyclovir, 1-(2-deoxy-2'"'"'-fluoro-1-β

-D-arabinofuranosyl)-5-iodocytosine (FIAC) or 1(2'"'"'-deoxy-2'"'"'-fluoro-1-β

-D-arabinofuranosyl)5-iodouracil (FIAU).

25. A pharmaceutical product according to claim 19, comprising a therapeutic polynucleotide.

26. A pharmaceutical product according to claim 25, wherein said therapeutic polynucleotide is a ribozyme or an antisense RNA or DNA.

27. A pharmaceutical preparation according to claim 26, wherein said ribozyme or antisense DNA or RNA is directed against HIV.

28. A pharmaceutical preparation according to claim 26, wherein said ribozyme or antisense DNA or RNA is directed against the rev transactivator.

29. A pharmaceutical preparation according to claim 25, wherein said therapeutic polynucleotide is a 28-mer phosphorothioate antisense polynucleotide.

30. A pharmaceutical preparation according to claim 25, wherein said therapeutic polynucleotide codes for a therapeutic polypeptide.

31. The pharmaceutical preparation of claim 30, wherein said therapeutic polypeptide is deficient or absent in a disease state.

32. The pharmaceutical preparation of claim 30, wherein said therapeutic polypeptide is a natural hormone or a synthetic analog thereof.

33. The pharmaceutical preparation of claim 30, wherein said therapeutic polypeptide is an immunogen.

34. The pharmaceutical preparation of claim 27, wherein said therapeutic agent is a protein or peptide.

35. A pharmaceutical preparation for topical use comprising a compound having the structure set forth in claim 2 or 3, and a pharmacologically effective amount of a therapeutic agent in a pharmaceutically acceptable vehicle.

36. The pharmaceutical preparation of claim 25, wherein said therapeutic agent is a corticosteroid, a nonsteroidal anti-inflammatory agent, an antibiotic, an antifungal agent, an oxidant, or an antiviral nucleoside.

37. The pharmaceutical preparation of claim 25, wherein said therapeutic agent is a protein, a polypeptide, or a therapeutic polynucleotide.

38. The pharmaceutical preparation of claim 25 comprising a therapeutic polynucleotide which is a ribozyme or an antisense RNA or DNA sequence.

39. The pharmaceutical preparation of claim 25 comprising a therapeutic polynucleotide coding for a gene product that is deficient or absent in a disease state.

40. The pharmaceutical preparation of claim 25 comprising a therapeutic polynucleotide coding for an immunogenic peptide, a natural hormone, or a synthetic analogue of a natural hormone.

41. A pharmaceutical preparation for topical use in the treatment of Herpes simplex, comprising a compound having the structure set forth in claim 2 or 3 together with a pharmacologically effective concentration of acyclovir, gancyclovir, 1-(2-deoxy-2'"'"'-fluoro-1-β

-D-arabinofuranosyl)-5-iodocytosine (FIAC) or 1(2'"'"'-deoxy-2'"'"'-fluoro-1-β

-D-arabinofuranosyl)5-iodouracil (FIAU) in a pharmaceutically acceptable vehicle.

42. A method for introducing a biologically active agent into a cell of a plant or animal, comprising:

a. preparing lipid vesicles comprising a cationic lipid having a structure set forth in claim 2 or 3 and containing said biologically active agent;

b. contacting said cell with said lipid vesicles whereby said biologically active agent is taken up into said cell.

43. A method for introducing a biologically active agent into a cell of a plant or animal, comprising:

preparing lipid vesicles comprising a cationic lipid having a structure set forth in claim 2 or 3;

contacting said cell with a bioactive agent in the presence of said lipid vesicles, whereby said bioactive agent is taken up into said cell.

44. A method according to claim 43, wherein said contacting step occurs in vitro.

45. A method of treating a disease in a vertebrate, comprising the step of

administering a pharmaceutical preparation comprising a cationic lipid having a structure set forth in claim 2 or 3 and a pharmacologically effective amount of a therapeutic agent specific for the treatment of said disease, and permitting said therapeutic agent to be incorporated into at least one cell of said vertebrate, whereby said disease is effectively treated.

46. A method according to claim 45, comprising the administration of said preparation to the cells of said vertebrate in vitro, which cells are then returned to said vertebrate.

47. A method according to claim 45, comprising the topical application of said preparation to the skin or to a mucosal surface.

48. A method according to claim 45, comprising the injection of said preparation into body cavity or into the tissues of said vertebrate.

49. A method according to claim 45, comprising the oral administration of said preparation.

50. A method according to claim 45, wherein said biologically active agent is a polynucleotide.

51. A method according to claim 45, wherein said biologically active agent is DNA or mRNA coding for a polypeptide, and said polypeptide is expressed after said DNA or said mRNA is taken up into said cell.

52. A method according to claim 45 wherein said biologically active agent is a drug.

3. A formulation for transfection of polynucleotides and peptides into cells, comprising a compound having the structure ##STR22## or an optical isomer thereof, wherein Y¹ and Y² are different and are either --O--C(O)-- or --O--;

R¹ is C₁ to C₂₄ alkyl or alkenyl, or H;

R² is C₁ to C₂₄ alkyl or alkenyl;

R³, R⁴ and R⁵ are independently H, C₁ to C₁₄ alkyl, C₇ to C₁₁ aryl or alkaryl, or at least two of R³, R⁴ and R⁵ are taken together to form quinuclidino, piperidino, pyrrolidino, or morpholino; and

X is a non-toxic anion;

together with an effective transfection-promoting amount of a lysophosphatide.

4. A formulation for transfection of polynucleotides and peptides into cells, comprising a compound selected from the group consisting of 3,5-(N,N-dilysyl)-diaminobenxzoyl-3-(DL-1,2-dioleoyldimethylaminopropyl-.beta.-hydroxyethylamine;

3,5-(N,N-dilysyl)diaminobenxzoylglycyl-3-(DL-1,2-dioleoyl-dimethylaminopropyl-β

-hydroxyethylamine); and

L-spermine-5-carboxyl-3-(DL-1,2-dioleoyldimethylaminopropyl-β

-hydroxyethylamine) together with an effective transfection-promoting amount of a lysophosphatide.